Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but ...
Data-driven therapeutics company Octant Bio is exploring new frontiers of drug development with $80 million in-pocket and a freshly signed Big Pharma partnership. Octant—a historical instrument used ...
EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback